Krystal Biotech (KRYS) EBT Margin (2021 - 2025)
Historic EBT Margin for Krystal Biotech (KRYS) over the last 4 years, with Q4 2025 value amounting to 47.74%.
- Krystal Biotech's EBT Margin fell 56100.0% to 47.74% in Q4 2025 from the same period last year, while for Dec 2025 it was 48.69%, marking a year-over-year increase of 158700.0%. This contributed to the annual value of 48.69% for FY2025, which is 158700.0% up from last year.
- Per Krystal Biotech's latest filing, its EBT Margin stood at 47.74% for Q4 2025, which was down 56100.0% from 49.05% recorded in Q3 2025.
- In the past 5 years, Krystal Biotech's EBT Margin registered a high of 1059.79% during Q1 2021, and its lowest value of 2.06% during Q1 2024.
- Its 4-year average for EBT Margin is 212.5%, with a median of 48.7% in 2025.
- Per our database at Business Quant, Krystal Biotech's EBT Margin plummeted by -9082400bps in 2024 and then skyrocketed by 473700bps in 2025.
- Over the past 4 years, Krystal Biotech's EBT Margin (Quarter) stood at 1059.79% in 2021, then plummeted by -98bps to 25.29% in 2023, then surged by 111bps to 53.35% in 2024, then decreased by -11bps to 47.74% in 2025.
- Its EBT Margin was 47.74% in Q4 2025, compared to 49.05% in Q3 2025 and 48.7% in Q2 2025.